Enliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - Should You Sell?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price traded down 9.1% on Tuesday . The company traded as low as $16.57 and last traded at $16.25. 65,184 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 280,300 shares. The stock had previously closed at $17.87.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Enliven Therapeutics Trading Up 10.7 %

The firm's fifty day moving average price is $20.31 and its 200-day moving average price is $23.29. The firm has a market cap of $809.06 million, a price-to-earnings ratio of -8.69 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Monday, April 7th. The shares were sold at an average price of $18.04, for a total transaction of $120,272.68. Following the completion of the sale, the chief operating officer now owns 316,643 shares in the company, valued at $5,712,239.72. This represents a 2.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now directly owns 23,000 shares in the company, valued at $490,590. The trade was a 12.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,751 shares of company stock worth $1,178,263 in the last quarter. 29.20% of the stock is owned by insiders.

Remove Ads

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Polar Capital Holdings Plc grew its stake in shares of Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth $15,106,000. Lord Abbett & CO. LLC purchased a new position in Enliven Therapeutics in the 3rd quarter valued at $8,199,000. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after buying an additional 290,153 shares during the period. Finally, FMR LLC increased its stake in Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after buying an additional 199,692 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.